<PAGE>
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 8, 1998
CVS CORPORATION
--------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
<TABLE>
<S> <C> <C>
Delaware 1-1011 05-0494040
- ------------------------ ------------------------ ------------------------------------
(State of Incorporation) (Commission File Number) (IRS Employer Identification Number)
</TABLE>
<TABLE>
<S> <C>
One CVS Drive
Woonsocket, Rhode Island 02895
---------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
</TABLE>
(401) 765-1500
------------------------------------------------------
(Registrant's telephone number, including area code)
---------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
<PAGE>
ITEM 5. Other Events
CVS Corporation ("CVS") through this filing complies with a
covenant contained in its Merger Agreement with Arbor Drugs,
Inc. ("Arbor") that requires CVS to report interim financial
results that include a 30-day period following the effective
date of the merger of Arbor and a wholly-owned subsidiary of CVS
(the "Merger"). The Merger was consummated on March 31, 1998.
For the 30-day period ending April 30, 1998, CVS reported
net sales of $1.24 billion and net earnings of $42.2 million,
excluding a non-recurring $114.0 million after-tax charge
recorded in connection with the Merger. Including the
non-recurring charge, CVS reported a net loss of $71.8 million
for the 30-day interim period.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CVS CORPORATION
(Registrant)
May 8, 1998 /s/ Charles C. Conaway
----------------------------
CHARLES C. CONAWAY
Executive Vice President and
Chief Financial Officer
3
